Loading...

Joseph Witztum

TitleRecall Faculty
InstitutionUniversity of California San Diego
DepartmentMedicine
Address9500 Gilman Drive #0682
La Jolla CA 92093
Phone858-534-4347
vCardDownload vCard

    Collapse Research 
    Collapse Research Activities and Funding
    Role of Immune Mechanisms in Athersclerosis and Inflammation
    NIH/NHLBI P01HL088093Apr 1, 2007 - Apr 30, 2019
    Role: Principal Investigator
    Development of a Vaccine Approach to Inhibit Atherosclerosis
    NIH/NHLBI R01HL086559Feb 10, 2007 - Jan 31, 2013
    Role: Principal Investigator
    LIPID MAPS
    NIH/NIGMS U54GM069338Aug 12, 2003 - Jul 31, 2014
    Role: Co-Investigator
    Role of B-1 Lymphocytes in Athergenesis
    NIH/NHLBI R01HL069464Sep 30, 2001 - Jul 31, 2005
    Role: Principal Investigator
    Discovery and Development of Therapeutic Genes for CHF
    NIH P01HL066941Sep 29, 2000 - Jun 30, 2018
    Role: Co-Investigator
    B-LYMPHOCYTE MEDIATED IMMUNE MECHANISMS IN ATHEROGENESIS
    NIH/NHLBI R01HL064833Jun 1, 2000 - May 31, 2004
    Role: Principal Investigator
    SCOR in Molecular Medicine and Atherosclerosis
    NIH/NHLBI P50HL056989Apr 23, 1997 - Mar 31, 2008
    Role: Principal Investigator
    Anticardiolipin Antibodies and Oxidized Phospholipids
    NIH/NHLBI R01HL057505Jan 1, 1997 - Jul 31, 2006
    Role: Principal Investigator
    IVEM and Image Analysis Resource
    NIH/NCRR P41RR004050Dec 12, 1988 - Mar 31, 2014
    Role: Co-Investigator
    APOLIPOPROTEIN E DEFICIENCY AND ATHEROSCLEROSIS
    NIH/NHLBI R01HL039608Jul 1, 1988 - Sep 29, 1991
    Role: Principal Investigator
    Experimental Endocrinology and Metabolism
    NIH/NIDDK T32DK007044Sep 15, 1978 - Mar 31, 2021
    Role: Principal Investigator
    SCOR IN ARTERIOSCLEROSIS
    NIH P50HL014197Dec 1, 1976 - Apr 30, 1997
    Role: Co-Investigator
    General Clinical Research Center
    NIH/NCRR M01RR000827Mar 1, 1974 - Nov 30, 2010
    Role: Co-Investigator

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. van Capelleveen JC, Lee SR, Verbeek R, Kastelein JJP, Wareham NJ, Stroes ESG, Hovingh GK, Khaw KT, Boekholdt SM, Witztum JL, Tsimikas S. Relationship of lipoprotein-associated apolipoprotein C-III with lipid variables and coronary artery disease risk: The EPIC-Norfolk prospective population study. J Clin Lipidol. 2018 Aug 29. PMID: 30249512.
      View in: PubMed
    2. Tsimikas S, Fazio S, Viney NJ, Xia S, Witztum JL, Marcovina SM. Relationship of lipoprotein(a) molar concentrations and mass according to lipoprotein(a) thresholds and apolipoprotein(a) isoform size. J Clin Lipidol. 2018 Jul 20. PMID: 30100157.
      View in: PubMed
    3. Que X, Hung MY, Yeang C, Gonen A, Prohaska TA, Sun X, Diehl C, Määttä A, Gaddis DE, Bowden K, Pattison J, MacDonald JG, Ylä-Herttuala S, Mellon PL, Hedrick CC, Ley K, Miller YI, Glass CK, Peterson KL, Binder CJ, Tsimikas S, Witztum JL. Publisher Correction: Oxidized phospholipids are proinflammatory and proatherogenic in hypercholesterolaemic mice. Nature. 2018 Jul 16. PMID: 30013121.
      View in: PubMed
    4. Ambrogini E, Que X, Wang S, Yamaguchi F, Weinstein RS, Tsimikas S, Manolagas SC, Witztum JL, Jilka RL. Oxidation-specific epitopes restrain bone formation. Nat Commun. 2018 Jun 06; 9(1):2193. PMID: 29875355.
      View in: PubMed
    5. Que X, Hung MY, Yeang C, Gonen A, Prohaska TA, Sun X, Diehl C, Määttä A, Gaddis DE, Bowden K, Pattison J, MacDonald JG, Ylä-Herttuala S, Mellon PL, Hedrick CC, Ley K, Miller YI, Glass CK, Peterson KL, Binder CJ, Tsimikas S, Witztum JL. Oxidized phospholipids are proinflammatory and proatherogenic in hypercholesterolaemic mice. Nature. 2018 Jun 06. PMID: 29875409.
      View in: PubMed
    6. Blom DJ, O'Dea L, Digenio A, Alexander VJ, Karwatowska-Prokopczuk E, Williams KR, Hemphill L, Muñiz-Grijalvo O, Santos RD, Baum S, Witztum JL. Characterizing familial chylomicronemia syndrome: Baseline data of the APPROACH study. J Clin Lipidol. 2018 Sep - Oct; 12(5):1234-1243.e5. PMID: 30318066.
      View in: PubMed
    7. Yeang C, Hasanally D, Que X, Hung MY, Stemankovic A, Chan D, Chaudhary R, Margulets V, Edel AL, Hoshijima M, Gu Y, Bradford W, Dalton N, Miu P, Cheung DYC, Jassal DS, Pierce GN, Peterson KL, Kirshenbaum LA, Witztum JL, Tsimikas S, Ravandi A. Reduction of Myocardial Ischemia-Reperfusion Injury by Inactivating Oxidized Phospholipids. Cardiovasc Res. 2018 May 30. PMID: 29850765.
      View in: PubMed
    8. Davidson M, Stevenson M, Hsieh A, Ahmad Z, Roeters van Lennep J, Crowson C, Witztum JL. The burden of familial chylomicronemia syndrome: Results from the global IN-FOCUS study. J Clin Lipidol. 2018 Apr 26. PMID: 29784572.
      View in: PubMed
    9. Hegele RA, Berberich AJ, Ban MR, Wang J, Digenio A, Alexander VJ, D'Erasmo L, Arca M, Jones A, Bruckert E, Stroes ES, Bergeron J, Civeira F, Witztum JL, Gaudet D. Clinical and biochemical features of different molecular etiologies of familial chylomicronemia. J Clin Lipidol. 2018 Apr 04. PMID: 29748148.
      View in: PubMed
    10. Crooke ST, Witztum JL, Bennett CF, Baker BF. RNA-Targeted Therapeutics. Cell Metab. 2018 Apr 03; 27(4):714-739. PMID: 29617640.
      View in: PubMed
    11. Viney NJ, Yeang C, Yang X, Xia S, Witztum JL, Tsimikas S. Relationship between "LDL-C", estimated true LDL-C, apolipoprotein B-100, and PCSK9 levels following lipoprotein(a) lowering with an antisense oligonucleotide. J Clin Lipidol. 2018 Mar 01. PMID: 29574075.
      View in: PubMed
    12. Prohaska TA, Que X, Diehl CJ, Hendrikx S, Chang MW, Jepsen K, Glass CK, Benner C, Witztum JL. Massively Parallel Sequencing of Peritoneal and Splenic B Cell Repertoires Highlights Unique Properties of B-1 Cell Antibodies. J Immunol. 2018 Mar 01; 200(5):1702-1717. PMID: 29378911.
      View in: PubMed
    13. Senders ML, Que X, Cho YS, Yeang C, Groenen H, Fay F, Calcagno C, Meerwaldt AE, Green S, Miu P, Lobatto ME, Reiner T, Fayad ZA, Witztum JL, Mulder WJM, Pérez-Medina C, Tsimikas S. PET/MR Imaging of Malondialdehyde-Acetaldehyde Epitopes With a Human Antibody Detects Clinically Relevant Atherothrombosis. J Am Coll Cardiol. 2018 Jan 23; 71(3):321-335. PMID: 29348025.
      View in: PubMed
    14. Tsimikas S, Fazio S, Ferdinand KC, Ginsberg HN, Koschinsky ML, Marcovina SM, Moriarty PM, Rader DJ, Remaley AT, Reyes-Soffer G, Santos RD, Thanassoulis G, Witztum JL, Danthi S, Olive M, Liu L. NHLBI Working Group Recommendations to Reduce Lipoprotein(a)-Mediated Risk of Cardiovascular Disease and Aortic Stenosis. J Am Coll Cardiol. 2018 Jan 16; 71(2):177-192. PMID: 29325642.
      View in: PubMed
    15. Naka KK, Bechlioullis A, Marini A, Sionis D, Vakalis K, Triantis G, Wilkins L, Rogus J, Kornman KS, Witztum JL, Doucette-Stamm L, Michalis LK, Tsimikas S. Interleukin-1 genotypes modulate the long-term effect of lipoprotein(a) on cardiovascular events: The Ioannina Study. J Clin Lipidol. 2018 Mar - Apr; 12(2):338-347. PMID: 29310992.
      View in: PubMed
    16. Yin X, Baig F, Haudebourg E, Blankley RT, Gandhi T, Müller S, Reiter L, Hinterwirth H, Pechlaner R, Tsimikas S, Santer P, Willeit J, Kiechl S, Witztum JL, Sullivan A, Mayr M. Plasma Proteomics for Epidemiology: Increasing Throughput With Standard-Flow Rates. Circ Cardiovasc Genet. 2017 Dec; 10(6). PMID: 29237681.
      View in: PubMed
    17. Marcovina SM, Viney NJ, Hughes SG, Xia S, Witztum JL, Tsimikas S. Temporal variability in lipoprotein(a) levels in patients enrolled in the placebo arms of IONIS-APO(a)Rx and IONIS-APO(a)-LRx antisense oligonucleotide clinical trials. J Clin Lipidol. 2018 Jan - Feb; 12(1):122-129.e2. PMID: 29174389.
      View in: PubMed
    18. Hartikainen J, Hassinen I, Hedman A, Kivelä A, Saraste A, Knuuti J, Husso M, Mussalo H, Hedman M, Rissanen TT, Toivanen P, Heikura T, Witztum JL, Tsimikas S, Ylä-Herttuala S. Adenoviral intramyocardial VEGF-D?N?C gene transfer increases myocardial perfusion reserve in refractory angina patients: a phase I/IIa study with 1-year follow-up. Eur Heart J. 2017 Sep 01; 38(33):2547-2555. PMID: 28903476.
      View in: PubMed
    19. Gaudet D, Digenio A, Alexander V, Arca M, Jones A, Stroes E, Bergeron J, Civeira F, Hemphill L, Blom D, Flaim J, Hughes S, Geary R, Tsimikas S, Witztum J, Bruckert E. The approach study: a randomized, double-blind, placebo-controlled, phase 3 study of volanesorsen administered subcutaneously to patients with familial chylomicronemia syndrome (FCS). Atherosclerosis. 2017 Aug; 263:e10. PMID: 29365426.
      View in: PubMed
    20. Torzewski M, Ravandi A, Yeang C, Edel A, Bhindi R, Kath S, Twardowski L, Schmid J, Yang X, Franke UFW, Witztum JL, Tsimikas S. Lipoprotein(a) Associated Molecules are Prominent Components in Plasma and Valve Leaflets in Calcific Aortic Valve Stenosis. JACC Basic Transl Sci. 2017 Jun; 2(3):229-240. PMID: 29147686.
      View in: PubMed
    21. Kamstrup PR, Hung MY, Witztum JL, Tsimikas S, Nordestgaard BG. Oxidized Phospholipids and Risk of Calcific Aortic Valve Disease: The Copenhagen General Population Study. Arterioscler Thromb Vasc Biol. 2017 Aug; 37(8):1570-1578. PMID: 28572160.
      View in: PubMed
    22. Graham MJ, Lee RG, Brandt TA, Tai LJ, Fu W, Peralta R, Yu R, Hurh E, Paz E, McEvoy BW, Baker BF, Pham NC, Digenio A, Hughes SG, Geary RS, Witztum JL, Crooke RM, Tsimikas S. Cardiovascular and Metabolic Effects of ANGPTL3 Antisense Oligonucleotides. N Engl J Med. 2017 07 20; 377(3):222-232. PMID: 28538111.
      View in: PubMed
    23. van Capelleveen JC, Bernelot Moens SJ, Yang X, Kastelein JJP, Wareham NJ, Zwinderman AH, Stroes ESG, Witztum JL, Hovingh GK, Khaw KT, Boekholdt SM, Tsimikas S. Apolipoprotein C-III Levels and Incident Coronary Artery Disease Risk: The EPIC-Norfolk Prospective Population Study. Arterioscler Thromb Vasc Biol. 2017 Jun; 37(6):1206-1212. PMID: 28473441.
      View in: PubMed
    24. Prasad A, Clopton P, Ayers C, Khera A, de Lemos JA, Witztum JL, Tsimikas S. Relationship of Autoantibodies to MDA-LDL and ApoB-Immune Complexes to Sex, Ethnicity, Subclinical Atherosclerosis, and Cardiovascular Events. Arterioscler Thromb Vasc Biol. 2017 Jun; 37(6):1213-1221. PMID: 28473443.
      View in: PubMed
    25. Saleheen D, Haycock PC, Zhao W, Rasheed A, Taleb A, Imran A, Abbas S, Majeed F, Akhtar S, Qamar N, Zaman KS, Yaqoob Z, Saghir T, Rizvi SNH, Memon A, Mallick NH, Ishaq M, Rasheed SZ, Memon FU, Mahmood K, Ahmed N, Frossard P, Tsimikas S, Witztum JL, Marcovina S, Sandhu M, Rader DJ, Danesh J. Apolipoprotein(a) isoform size, lipoprotein(a) concentration, and coronary artery disease: a mendelian randomisation analysis. Lancet Diabetes Endocrinol. 2017 07; 5(7):524-533. PMID: 28408323.
      View in: PubMed
    26. Davidson M, Stevenson M, Hsieh A, Ahmad Z, Crowson C, Witztum JL. The burden of familial chylomicronemia syndrome: interim results from the IN-FOCUS study. Expert Rev Cardiovasc Ther. 2017 May; 15(5):415-423. PMID: 28338353.
      View in: PubMed
    27. Capoulade R, Chan KL, Mathieu P, Bossé Y, Dumesnil JG, Tam JW, Teo KK, Yang X, Witztum JL, Arsenault BJ, Després JP, Pibarot P, Tsimikas S. Autoantibodies and immune complexes to oxidation-specific epitopes and progression of aortic stenosis: Results from the ASTRONOMER trial. Atherosclerosis. 2017 May; 260:1-7. PMID: 28319871.
      View in: PubMed
    28. Pechlaner R, Tsimikas S, Yin X, Willeit P, Baig F, Santer P, Oberhollenzer F, Egger G, Witztum JL, Alexander VJ, Willeit J, Kiechl S, Mayr M. Very-Low-Density Lipoprotein-Associated Apolipoproteins Predict Cardiovascular Events and Are Lowered by Inhibition of APOC-III. J Am Coll Cardiol. 2017 Feb 21; 69(7):789-800. PMID: 28209220.
      View in: PubMed
    29. Crooke ST, Baker BF, Witztum JL, Kwoh TJ, Pham NC, Salgado N, McEvoy BW, Cheng W, Hughes SG, Bhanot S, Geary RS. The Effects of 2'-O-Methoxyethyl Containing Antisense Oligonucleotides on Platelets in Human Clinical Trials. Nucleic Acid Ther. 2017 Jun; 27(3):121-129. PMID: 28145801.
      View in: PubMed
    30. Byun YS, Yang X, Bao W, DeMicco D, Laskey R, Witztum JL, Tsimikas S. Oxidized Phospholipids on Apolipoprotein B-100 and Recurrent Ischemic Events Following Stroke or Transient Ischemic Attack. J Am Coll Cardiol. 2017 Jan 17; 69(2):147-158. PMID: 28081824.
      View in: PubMed
    31. Ito A, Hong C, Oka K, Salazar JV, Diehl C, Witztum JL, Diaz M, Castrillo A, Bensinger SJ, Chan L, Tontonoz P. Cholesterol Accumulation in CD11c+ Immune Cells Is a Causal and Targetable Factor in Autoimmune Disease. Immunity. 2016 12 20; 45(6):1311-1326. PMID: 28002731.
      View in: PubMed
    32. Lee SR, Prasad A, Choi YS, Xing C, Clopton P, Witztum JL, Tsimikas S. LPA Gene, Ethnicity, and Cardiovascular Events. Circulation. 2017 Jan 17; 135(3):251-263. PMID: 27831500.
      View in: PubMed
    33. Viney NJ, van Capelleveen JC, Geary RS, Xia S, Tami JA, Yu RZ, Marcovina SM, Hughes SG, Graham MJ, Crooke RM, Crooke ST, Witztum JL, Stroes ES, Tsimikas S. Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials. Lancet. 2016 11 05; 388(10057):2239-2253. PMID: 27665230.
      View in: PubMed
    34. van der Valk FM, Bekkering S, Kroon J, Yeang C, Van den Bossche J, van Buul JD, Ravandi A, Nederveen AJ, Verberne HJ, Scipione C, Nieuwdorp M, Joosten LA, Netea MG, Koschinsky ML, Witztum JL, Tsimikas S, Riksen NP, Stroes ES. Oxidized Phospholipids on Lipoprotein(a) Elicit Arterial Wall Inflammation and an Inflammatory Monocyte Response in Humans. Circulation. 2016 Aug 23; 134(8):611-24. PMID: 27496857; PMCID: PMC4995139 [Available on 08/23/17].
    35. Gordts PL, Nock R, Son NH, Ramms B, Lew I, Gonzales JC, Thacker BE, Basu D, Lee RG, Mullick AE, Graham MJ, Goldberg IJ, Crooke RM, Witztum JL, Esko JD. ApoC-III inhibits clearance of triglyceride-rich lipoproteins through LDL family receptors. J Clin Invest. 2016 Aug 01; 126(8):2855-66. PMID: 27400128; PMCID: PMC4966320 [Available on 11/01/16].
    36. Binder CJ, Papac-Milicevic N, Witztum JL. Innate sensing of oxidation-specific epitopes in health and disease. Nat Rev Immunol. 2016 08; 16(8):485-97. PMID: 27346802.
      View in: PubMed
    37. Duell PB, Santos RD, Kirwan BA, Witztum JL, Tsimikas S, Kastelein JJP. Long-term mipomersen treatment is associated with a reduction in cardiovascular events in patients with familial hypercholesterolemia. J Clin Lipidol. 2016 Jul-Aug; 10(4):1011-1021. PMID: 27578134.
      View in: PubMed
    38. Yeang C, Hung MY, Byun YS, Clopton P, Yang X, Witztum JL, Tsimikas S. Effect of therapeutic interventions on oxidized phospholipids on apolipoprotein B100 and lipoprotein(a). J Clin Lipidol. 2016 May-Jun; 10(3):594-603. PMID: 27206947.
      View in: PubMed
    39. Gruber S, Hendrikx T, Tsiantoulas D, Ozsvar-Kozma M, Göderle L, Mallat Z, Witztum JL, Shiri-Sverdlov R, Nitschke L, Binder CJ. Sialic Acid-Binding Immunoglobulin-like Lectin G Promotes Atherosclerosis and Liver Inflammation by Suppressing the Protective Functions of B-1 Cells. Cell Rep. 2016 Mar 15; 14(10):2348-61. PMID: 26947073; PMCID: PMC4802221.
    40. Harmon DB, Srikakulapu P, Kaplan JL, Oldham SN, McSkimming C, Garmey JC, Perry HM, Kirby JL, Prohaska TA, Gonen A, Hallowell P, Schirmer B, Tsimikas S, Taylor AM, Witztum JL, McNamara CA. Protective Role for B-1b B Cells and IgM in Obesity-Associated Inflammation, Glucose Intolerance, and Insulin Resistance. Arterioscler Thromb Vasc Biol. 2016 Apr; 36(4):682-91. PMID: 26868208; PMCID: PMC4808436 [Available on 04/01/17].
    41. Yang X, Lee SR, Choi YS, Alexander VJ, Digenio A, Yang Q, Miller YI, Witztum JL, Tsimikas S. Reduction in lipoprotein-associated apoC-III levels following volanesorsen therapy: phase 2 randomized trial results. J Lipid Res. 2016 Apr; 57(4):706-13. PMID: 26848137; PMCID: PMC4808774 [Available on 04/01/17].
    42. Witztum JL, Ginsberg HN. Lipoprotein (a): Coming of Age at Last. J Lipid Res. 2016 Mar; 57(3):336-9. PMID: 26839334; PMCID: PMC4766984 [Available on 03/01/17].
    43. Verbeek R, Boekholdt SM, Stoekenbroek RM, Hovingh GK, Witztum JL, Wareham NJ, Sandhu MS, Khaw KT, Tsimikas S. Population and assay thresholds for the predictive value of lipoprotein (a) for coronary artery disease: the EPIC-Norfolk Prospective Population Study. J Lipid Res. 2016 Apr; 57(4):697-705. PMID: 26828068; PMCID: PMC4808778 [Available on 04/01/17].
    44. Foks AC, Engelbertsen D, Kuperwaser F, Alberts-Grill N, Gonen A, Witztum JL, Lederer J, Jarolim P, DeKruyff RH, Freeman GJ, Lichtman AH. Blockade of Tim-1 and Tim-4 Enhances Atherosclerosis in Low-Density Lipoprotein Receptor-Deficient Mice. Arterioscler Thromb Vasc Biol. 2016 Mar; 36(3):456-65. PMID: 26821944; PMCID: PMC4853762 [Available on 03/01/17].
    45. Capoulade R, Chan KL, Yeang C, Mathieu P, Bossé Y, Dumesnil JG, Tam JW, Teo KK, Mahmut A, Yang X, Witztum JL, Arsenault BJ, Després JP, Pibarot P, Tsimikas S. Oxidized Phospholipids, Lipoprotein(a), and Progression of Calcific Aortic Valve Stenosis. J Am Coll Cardiol. 2015 Sep 15; 66(11):1236-1246. PMID: 26361154.
      View in: PubMed
    46. Witztum JL. CEP Is an Important and Ubiquitous Oxidation Specific Epitope Recognized by Innate Pattern Recognition Receptors. Circ Res. 2015 Jul 31; 117(4):305-8. PMID: 26227873; PMCID: PMC4816067.
    47. Gaudet D, Alexander VJ, Baker BF, Brisson D, Tremblay K, Singleton W, Geary RS, Hughes SG, Viney NJ, Graham MJ, Crooke RM, Witztum JL, Brunzell JD, Kastelein JJ. Antisense Inhibition of Apolipoprotein C-III in Patients with Hypertriglyceridemia. N Engl J Med. 2015 Jul 30; 373(5):438-47. PMID: 26222559.
      View in: PubMed
    48. Glass CK, Witztum JL. Daniel Steinberg, 1922-2015. Proc Natl Acad Sci U S A. 2015 Aug 11; 112(32):9791-2. PMID: 26209653; PMCID: PMC4538637.
    49. Tsimikas S, Viney NJ, Hughes SG, Singleton W, Graham MJ, Baker BF, Burkey JL, Yang Q, Marcovina SM, Geary RS, Crooke RM, Witztum JL. Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study. Lancet. 2015 Oct 10; 386(10002):1472-83. PMID: 26210642.
      View in: PubMed
    50. Rosenfeld SM, Perry HM, Gonen A, Prohaska TA, Srikakulapu P, Grewal S, Das D, McSkimming C, Taylor AM, Tsimikas S, Bender TP, Witztum JL, McNamara CA. B-1b Cells Secrete Atheroprotective IgM and Attenuate Atherosclerosis. Circ Res. 2015 Jul 17; 117(3):e28-39. PMID: 26082558.
      View in: PubMed
    51. Liu C, Gates KP, Fang L, Amar MJ, Schneider DA, Geng H, Huang W, Kim J, Pattison J, Zhang J, Witztum JL, Remaley AT, Dong PD, Miller YI. Apoc2 loss-of-function zebrafish mutant as a genetic model of hyperlipidemia. Dis Model Mech. 2015 Aug 01; 8(8):989-98. PMID: 26044956; PMCID: PMC4527288.
    52. Yeang C, Witztum JL, Tsimikas S. 'LDL-C'?=?LDL-C?+?Lp(a)-C: implications of achieved ultra-low LDL-C levels in the proprotein convertase subtilisin/kexin type 9 era of potent LDL-C lowering. Curr Opin Lipidol. 2015 Jun; 26(3):169-78. PMID: 25943842.
      View in: PubMed
    53. Rao F, Schork AJ, Maihofer AX, Nievergelt CM, Marcovina SM, Miller ER, Witztum JL, O'Connor DT, Tsimikas S. Heritability of Biomarkers of Oxidized Lipoproteins: Twin Pair Study. Arterioscler Thromb Vasc Biol. 2015 Jul; 35(7):1704-11. PMID: 25953646; PMCID: PMC4483152.
    54. Byun YS, Lee JH, Arsenault BJ, Yang X, Bao W, DeMicco D, Laskey R, Witztum JL, Tsimikas S. Relationship of oxidized phospholipids on apolipoprotein B-100 to cardiovascular outcomes in patients treated with intensive versus moderate atorvastatin therapy: the TNT trial. J Am Coll Cardiol. 2015 Apr 07; 65(13):1286-1295. PMID: 25835440; PMCID: PMC4386070.
    55. Santos RD, Raal FJ, Catapano AL, Witztum JL, Steinhagen-Thiessen E, Tsimikas S. Mipomersen, an antisense oligonucleotide to apolipoprotein B-100, reduces lipoprotein(a) in various populations with hypercholesterolemia: results of 4 phase III trials. Arterioscler Thromb Vasc Biol. 2015 Mar; 35(3):689-99. PMID: 25614280; PMCID: PMC4344404.
    56. Gorden DL, Myers DS, Ivanova PT, Fahy E, Maurya MR, Gupta S, Min J, Spann NJ, McDonald JG, Kelly SL, Duan J, Sullards MC, Leiker TJ, Barkley RM, Quehenberger O, Armando AM, Milne SB, Mathews TP, Armstrong MD, Li C, Melvin WV, Clements RH, Washington MK, Mendonsa AM, Witztum JL, Guan Z, Glass CK, Murphy RC, Dennis EA, Merrill AH, Russell DW, Subramaniam S, Brown HA. Biomarkers of NAFLD progression: a lipidomics approach to an epidemic. J Lipid Res. 2015 Mar; 56(3):722-36. PMID: 25598080; PMCID: PMC4340319.
    57. Choi SH, Gonen A, Diehl CJ, Kim J, Almazan F, Witztum JL, Miller YI. SYK regulates macrophage MHC-II expression via activation of autophagy in response to oxidized LDL. Autophagy. 2015; 11(5):785-95. PMID: 25946330; PMCID: PMC4509444.
    58. Handa JT, Tagami M, Ebrahimi K, Leibundgut G, Janiak A, Witztum JL, Tsimikas S. Lipoprotein(A) with An Intact Lysine Binding Site Protects the Retina From an Age-Related Macular Degeneration Phenotype in Mice (An American Ophthalmological Society Thesis). Trans Am Ophthalmol Soc. 2015; 113:T5. PMID: 26538774; PMCID: PMC4601905.
    59. Fernandez JA, Deguchi H, Banka CL, Witztum JL, Griffin JH. Re-evaluation of the anticoagulant properties of high-density lipoprotein-brief report. Arterioscler Thromb Vasc Biol. 2015 Mar; 35(3):570-2. PMID: 25550205; PMCID: PMC4344393.
    60. Tsiantoulas D, Perkmann T, Afonyushkin T, Mangold A, Prohaska TA, Papac-Milicevic N, Millischer V, Bartel C, Hörkkö S, Boulanger CM, Tsimikas S, Fischer MB, Witztum JL, Lang IM, Binder CJ. Circulating microparticles carry oxidation-specific epitopes and are recognized by natural IgM antibodies. J Lipid Res. 2015 Feb; 56(2):440-8. PMID: 25525116; PMCID: PMC4306697.
    61. Gaudet D, Brisson D, Tremblay K, Alexander VJ, Singleton W, Hughes SG, Geary RS, Baker BF, Graham MJ, Crooke RM, Witztum JL. Targeting APOC3 in the familial chylomicronemia syndrome. N Engl J Med. 2014 Dec 04; 371(23):2200-6. PMID: 25470695.
      View in: PubMed
    62. Willeit P, Raschenberger J, Heydon EE, Tsimikas S, Haun M, Mayr A, Weger S, Witztum JL, Butterworth AS, Willeit J, Kronenberg F, Kiechl S. Leucocyte telomere length and risk of type 2 diabetes mellitus: new prospective cohort study and literature-based meta-analysis. PLoS One. 2014; 9(11):e112483. PMID: 25390655; PMCID: PMC4229188.
    63. Gordts PLSM, Foley EM, Lawrence R, Sinha R, Lameda-Diaz C, Deng L, Nock R, Glass CK, Erbilgin A, Lusis AJ, Witztum JL, Esko JD. Reducing macrophage proteoglycan sulfation increases atherosclerosis and obesity through enhanced type I interferon signaling. Cell Metab. 2014 Nov 04; 20(5):813-826. PMID: 25440058.
      View in: PubMed
    64. Pechlaner R, Willeit P, Summerer M, Santer P, Egger G, Kronenberg F, Demetz E, Weiss G, Tsimikas S, Witztum JL, Willeit K, Iglseder B, Paulweber B, Kedenko L, Haun M, Meisinger C, Gieger C, Müller-Nurasyid M, Peters A, Willeit J, Kiechl S. Heme oxygenase-1 gene promoter microsatellite polymorphism is associated with progressive atherosclerosis and incident cardiovascular disease. Arterioscler Thromb Vasc Biol. 2015 Jan; 35(1):229-36. PMID: 25359861; PMCID: PMC4317265.
    65. Baldan A, Gonen A, Choung C, Que X, Marquart TJ, Hernandez I, Bjorkhem I, Ford DA, Witztum JL, Tarling EJ. ABCG1 is required for pulmonary B-1 B cell and natural antibody homeostasis. J Immunol. 2014 Dec 01; 193(11):5637-48. PMID: 25339664; PMCID: PMC4239162.
    66. Briley-Saebo K, Yeang C, Witztum JL, Tsimikas S. Imaging of oxidation-specific epitopes with targeted nanoparticles to detect high-risk atherosclerotic lesions: progress and future directions. J Cardiovasc Transl Res. 2014 Nov; 7(8):719-36. PMID: 25297940; PMCID: PMC4233166.
    67. Willeit P, Kiechl S, Kronenberg F, Witztum JL, Santer P, Mayr M, Xu Q, Mayr A, Willeit J, Tsimikas S. Discrimination and net reclassification of cardiovascular risk with lipoprotein(a): prospective 15-year outcomes in the Bruneck Study. J Am Coll Cardiol. 2014 Sep 02; 64(9):851-60. PMID: 25169167.
      View in: PubMed
    68. Gonen A, Hansen LF, Turner WW, Montano EN, Que X, Rafia A, Chou MY, Wiesner P, Tsiantoulas D, Corr M, VanNieuwenhze MS, Tsimikas S, Binder CJ, Witztum JL, Hartvigsen K. Atheroprotective immunization with malondialdehyde-modified LDL is hapten specific and dependent on advanced MDA adducts: implications for development of an atheroprotective vaccine. J Lipid Res. 2014 Oct; 55(10):2137-55. PMID: 25143462; PMCID: PMC4174006.
    69. Tsiantoulas D, Diehl CJ, Witztum JL, Binder CJ. B cells and humoral immunity in atherosclerosis. Circ Res. 2014 May 23; 114(11):1743-56. PMID: 24855199; PMCID: PMC4066414.
    70. Wang M, Subramanian M, Abramowicz S, Murphy AJ, Gonen A, Witztum J, Welch C, Tabas I, Westerterp M, Tall AR. Interleukin-3/granulocyte macrophage colony-stimulating factor receptor promotes stem cell expansion, monocytosis, and atheroma macrophage burden in mice with hematopoietic ApoE deficiency. Arterioscler Thromb Vasc Biol. 2014 May; 34(5):976-84. PMID: 24651678; PMCID: PMC4091799.
    71. Ravandi A, Leibundgut G, Hung MY, Patel M, Hutchins PM, Murphy RC, Prasad A, Mahmud E, Miller YI, Dennis EA, Witztum JL, Tsimikas S. Release and capture of bioactive oxidized phospholipids and oxidized cholesteryl esters during percutaneous coronary and peripheral arterial interventions in humans. J Am Coll Cardiol. 2014 May 20; 63(19):1961-71. PMID: 24613321; PMCID: PMC4629781.
    72. Tsimikas S, Duff GW, Berger PB, Rogus J, Huttner K, Clopton P, Brilakis E, Kornman KS, Witztum JL. Pro-inflammatory interleukin-1 genotypes potentiate the risk of coronary artery disease and cardiovascular events mediated by oxidized phospholipids and lipoprotein(a). J Am Coll Cardiol. 2014 May 06; 63(17):1724-34. PMID: 24530664; PMCID: PMC4008715.
    73. Hilgendorf I, Theurl I, Gerhardt LM, Robbins CS, Weber GF, Gonen A, Iwamoto Y, Degousee N, Holderried TA, Winter C, Zirlik A, Lin HY, Sukhova GK, Butany J, Rubin BB, Witztum JL, Libby P, Nahrendorf M, Weissleder R, Swirski FK. Innate response activator B cells aggravate atherosclerosis by stimulating T helper-1 adaptive immunity. Circulation. 2014 Apr 22; 129(16):1677-87. PMID: 24488984; PMCID: PMC3997655.
    74. Tse K, Gonen A, Sidney J, Ouyang H, Witztum JL, Sette A, Tse H, Ley K. Atheroprotective Vaccination with MHC-II Restricted Peptides from ApoB-100. Front Immunol. 2013; 4:493. PMID: 24416033; PMCID: PMC3873602.
    75. Choi SH, Yin H, Ravandi A, Armando A, Dumlao D, Kim J, Almazan F, Taylor AM, McNamara CA, Tsimikas S, Dennis EA, Witztum JL, Miller YI. Polyoxygenated cholesterol ester hydroperoxide activates TLR4 and SYK dependent signaling in macrophages. PLoS One. 2013; 8(12):e83145. PMID: 24376657.
      View in: PubMed
    76. Hung MY, Witztum JL, Tsimikas S. New therapeutic targets for calcific aortic valve stenosis: the lipoprotein(a)-lipoprotein-associated phospholipase A2-oxidized phospholipid axis. J Am Coll Cardiol. 2014 Feb 11; 63(5):478-80. PMID: 24161316.
      View in: PubMed
    77. Perry HM, Oldham SN, Fahl SP, Que X, Gonen A, Harmon DB, Tsimikas S, Witztum JL, Bender TP, McNamara CA. Helix-loop-helix factor inhibitor of differentiation 3 regulates interleukin-5 expression and B-1a B cell proliferation. Arterioscler Thromb Vasc Biol. 2013 Dec; 33(12):2771-9. PMID: 24115031.
      View in: PubMed
    78. Montano EN, Boullier A, Almazan F, Binder CJ, Witztum JL, Hartvigsen K. Development and application of a nonradioactive binding assay of oxidized low-density lipoprotein to macrophage scavenger receptors. J Lipid Res. 2013 Nov; 54(11):3206-14. PMID: 23997238; PMCID: PMC3793625.
    79. Douglas RM, Bowden K, Pattison J, Peterson AB, Juliano J, Dalton ND, Gu Y, Alvarez E, Imamura T, Peterson KL, Witztum JL, Haddad GG, Li AC. Intermittent hypoxia and hypercapnia induce pulmonary artery atherosclerosis and ventricular dysfunction in low density lipoprotein receptor deficient mice. J Appl Physiol (1985). 2013 Dec; 115(11):1694-704. PMID: 23990245; PMCID: PMC3882740.
    80. Witztum JL, Lichtman AH. The influence of innate and adaptive immune responses on atherosclerosis. Annu Rev Pathol. 2014; 9:73-102. PMID: 23937439; PMCID: PMC3988528.
    81. Leibundgut G, Scipione C, Yin H, Schneider M, Boffa MB, Green S, Yang X, Dennis E, Witztum JL, Koschinsky ML, Tsimikas S. Determinants of binding of oxidized phospholipids on apolipoprotein (a) and lipoprotein (a). J Lipid Res. 2013 Oct; 54(10):2815-30. PMID: 23828779; PMCID: PMC3770094.
    82. Que X, Widhopf GF, Amir S, Hartvigsen K, Hansen LF, Woelkers D, Tsimikas S, Binder CJ, Kipps TJ, Witztum JL. IGHV1-69-encoded antibodies expressed in chronic lymphocytic leukemia react with malondialdehyde-acetaldehyde adduct, an immunodominant oxidation-specific epitope. PLoS One. 2013; 8(6):e65203. PMID: 23840319; PMCID: PMC3688726.
    83. Wiesner P, Tafelmeier M, Chittka D, Choi SH, Zhang L, Byun YS, Almazan F, Yang X, Iqbal N, Chowdhury P, Maisel A, Witztum JL, Handel TM, Tsimikas S, Miller YI. MCP-1 binds to oxidized LDL and is carried by lipoprotein(a) in human plasma. J Lipid Res. 2013 Jul; 54(7):1877-83. PMID: 23667177; PMCID: PMC3679389.
    84. Leibundgut G, Witztum JL, Tsimikas S. Oxidation-specific epitopes and immunological responses: Translational biotheranostic implications for atherosclerosis. Curr Opin Pharmacol. 2013 Apr; 13(2):168-79. PMID: 23541680; PMCID: PMC3844667.
    85. Bertoia ML, Pai JK, Lee JH, Taleb A, Joosten MM, Mittleman MA, Yang X, Witztum JL, Rimm EB, Tsimikas S, Mukamal KJ. Oxidation-specific biomarkers and risk of peripheral artery disease. J Am Coll Cardiol. 2013 May 28; 61(21):2169-79. PMID: 23541965; PMCID: PMC3756816.
    86. Lichtman AH, Binder CJ, Tsimikas S, Witztum JL. Adaptive immunity in atherogenesis: new insights and therapeutic approaches. J Clin Invest. 2013 Jan; 123(1):27-36. PMID: 23281407; PMCID: PMC3533280.
    87. Yigitkanli K, Pekcec A, Karatas H, Pallast S, Mandeville E, Joshi N, Smirnova N, Gazaryan I, Ratan RR, Witztum JL, Montaner J, Holman TR, Lo EH, van Leyen K. Inhibition of 12/15-lipoxygenase as therapeutic strategy to treat stroke. Ann Neurol. 2013 Jan; 73(1):129-35. PMID: 23192915; PMCID: PMC3563836.
    88. Yoshida H, Shoda T, Yanai H, Ikewaki K, Kurata H, Ito K, Furutani N, Tada N, Witztum JL, Tsimikas S. Effects of pitavastatin and atorvastatin on lipoprotein oxidation biomarkers in patients with dyslipidemia. Atherosclerosis. 2013 Jan; 226(1):161-4. PMID: 23174369.
      View in: PubMed
    89. Tsimikas S, Willeit P, Willeit J, Santer P, Mayr M, Xu Q, Mayr A, Witztum JL, Kiechl S. Oxidation-specific biomarkers, prospective 15-year cardiovascular and stroke outcomes, and net reclassification of cardiovascular events. J Am Coll Cardiol. 2012 Nov 20; 60(21):2218-29. PMID: 23122790.
      View in: PubMed
    90. Holleboom AG, Daniil G, Fu X, Zhang R, Hovingh GK, Schimmel AW, Kastelein JJ, Stroes ES, Witztum JL, Hutten BA, Tsimikas S, Hazen SL, Chroni A, Kuivenhoven JA. Lipid oxidation in carriers of lecithin:cholesterol acyltransferase gene mutations. Arterioscler Thromb Vasc Biol. 2012 Dec; 32(12):3066-75. PMID: 23023370; PMCID: PMC3610418.
    91. Turner WW, Hartvigsen K, Boullier A, Montano EN, Witztum JL, VanNieuwenhze MS. Design and synthesis of a stable oxidized phospholipid mimic with specific binding recognition for macrophage scavenger receptors. J Med Chem. 2012 Sep 27; 55(18):8178-82. PMID: 22934615; PMCID: PMC3465084.
    92. van Dijk RA, Kolodgie F, Ravandi A, Leibundgut G, Hu PP, Prasad A, Mahmud E, Dennis E, Curtiss LK, Witztum JL, Wasserman BA, Otsuka F, Virmani R, Tsimikas S. Differential expression of oxidation-specific epitopes and apolipoprotein(a) in progressing and ruptured human coronary and carotid atherosclerotic lesions. J Lipid Res. 2012 Dec; 53(12):2773-90. PMID: 22969153; PMCID: PMC3494262.
    93. Thimmulappa RK, Gang X, Kim JH, Sussan TE, Witztum JL, Biswal S. Oxidized phospholipids impair pulmonary antibacterial defenses: evidence in mice exposed to cigarette smoke. Biochem Biophys Res Commun. 2012 Sep 21; 426(2):253-9. PMID: 22935414; PMCID: PMC3495329.
    94. Purushothaman KR, Purushothaman M, Levy AP, Lento PA, Evrard S, Kovacic JC, Briley-Saebo KC, Tsimikas S, Witztum JL, Krishnan P, Kini A, Fayad ZA, Fuster V, Sharma SK, Moreno PR. Increased expression of oxidation-specific epitopes and apoptosis are associated with haptoglobin genotype: possible implications for plaque progression in human atherosclerosis. J Am Coll Cardiol. 2012 Jul 10; 60(2):112-9. PMID: 22766337.
      View in: PubMed
    95. Visser ME, Witztum JL, Stroes ES, Kastelein JJ. Antisense oligonucleotides for the treatment of dyslipidaemia. Eur Heart J. 2012 Jun; 33(12):1451-8. PMID: 22634577.
      View in: PubMed
    96. Arai K, Orsoni A, Mallat Z, Tedgui A, Witztum JL, Bruckert E, Tselepis AD, Chapman MJ, Tsimikas S. Acute impact of apheresis on oxidized phospholipids in patients with familial hypercholesterolemia. J Lipid Res. 2012 Aug; 53(8):1670-8. PMID: 22628616; PMCID: PMC3540845.
    97. Leibundgut G, Arai K, Orsoni A, Yin H, Scipione C, Miller ER, Koschinsky ML, Chapman MJ, Witztum JL, Tsimikas S. Oxidized phospholipids are present on plasminogen, affect fibrinolysis, and increase following acute myocardial infarction. J Am Coll Cardiol. 2012 Apr 17; 59(16):1426-37. PMID: 22497821; PMCID: PMC3333481.
    98. Amir S, Hartvigsen K, Gonen A, Leibundgut G, Que X, Jensen-Jarolim E, Wagner O, Tsimikas S, Witztum JL, Binder CJ. Peptide mimotopes of malondialdehyde epitopes for clinical applications in cardiovascular disease. J Lipid Res. 2012 Jul; 53(7):1316-26. PMID: 22508944; PMCID: PMC3371243.
    99. Barish GD, Yu RT, Karunasiri MS, Becerra D, Kim J, Tseng TW, Tai LJ, Leblanc M, Diehl C, Cerchietti L, Miller YI, Witztum JL, Melnick AM, Dent AL, Tangirala RK, Evans RM. The Bcl6-SMRT/NCoR cistrome represses inflammation to attenuate atherosclerosis. Cell Metab. 2012 Apr 04; 15(4):554-62. PMID: 22465074; PMCID: PMC3367511.
    100. Briley-Saebo KC, Nguyen TH, Saeboe AM, Cho YS, Ryu SK, Volkova ER, Volkava E, Dickson S, Leibundgut G, Wiesner P, Weisner P, Green S, Casanada F, Miller YI, Shaw W, Witztum JL, Fayad ZA, Tsimikas S. In vivo detection of oxidation-specific epitopes in atherosclerotic lesions using biocompatible manganese molecular magnetic imaging probes. J Am Coll Cardiol. 2012 Feb 07; 59(6):616-26. PMID: 22300697; PMCID: PMC3333483.
    101. Fang L, Green SR, Baek JS, Lee SH, Ellett F, Deer E, Lieschke GJ, Witztum JL, Tsimikas S, Miller YI. In vivo visualization and attenuation of oxidized lipid accumulation in hypercholesterolemic zebrafish. J Clin Invest. 2011 Dec; 121(12):4861-9. PMID: 22105168; PMCID: PMC3225997.
    102. Binder CJ, Witztum JL. Is atherosclerosis an allergic disease? Circ Res. 2011 Oct 28; 109(10):1103-4. PMID: 22034478.
      View in: PubMed
    103. Doran AC, Lipinski MJ, Oldham SN, Garmey JC, Campbell KA, Skaflen MD, Cutchins A, Lee DJ, Glover DK, Kelly KA, Galkina EV, Ley K, Witztum JL, Tsimikas S, Bender TP, McNamara CA. B-cell aortic homing and atheroprotection depend on Id3. Circ Res. 2012 Jan 06; 110(1):e1-12. PMID: 22034493; PMCID: PMC3253259.
    104. Tsimikas S, Miyanohara A, Hartvigsen K, Merki E, Shaw PX, Chou MY, Pattison J, Torzewski M, Sollors J, Friedmann T, Lai NC, Hammond HK, Getz GS, Reardon CA, Li AC, Banka CL, Witztum JL. Human oxidation-specific antibodies reduce foam cell formation and atherosclerosis progression. J Am Coll Cardiol. 2011 Oct 11; 58(16):1715-27. PMID: 21982317; PMCID: PMC3230644.
    105. Weismann D, Hartvigsen K, Lauer N, Bennett KL, Scholl HP, Charbel Issa P, Cano M, Brandstätter H, Tsimikas S, Skerka C, Superti-Furga G, Handa JT, Zipfel PF, Witztum JL, Binder CJ. Complement factor H binds malondialdehyde epitopes and protects from oxidative stress. Nature. 2011 Oct 05; 478(7367):76-81. PMID: 21979047; PMCID: PMC4826616.
    106. Taleb A, Witztum JL, Tsimikas S. Oxidized phospholipids on apoB-100-containing lipoproteins: a biomarker predicting cardiovascular disease and cardiovascular events. Biomark Med. 2011 Oct; 5(5):673-94. PMID: 22003918; PMCID: PMC3230643.
    107. Ravandi A, Boekholdt SM, Mallat Z, Talmud PJ, Kastelein JJ, Wareham NJ, Miller ER, Benessiano J, Tedgui A, Witztum JL, Khaw KT, Tsimikas S. Relationship of IgG and IgM autoantibodies and immune complexes to oxidized LDL with markers of oxidation and inflammation and cardiovascular events: results from the EPIC-Norfolk Study. J Lipid Res. 2011 Oct; 52(10):1829-36. PMID: 21821825; PMCID: PMC3173004.
    108. McMahon M, Skaggs BJ, Sahakian L, Grossman J, FitzGerald J, Ragavendra N, Charles-Schoeman C, Chernishof M, Gorn A, Witztum JL, Wong WK, Weisman M, Wallace DJ, La Cava A, Hahn BH. High plasma leptin levels confer increased risk of atherosclerosis in women with systemic lupus erythematosus, and are associated with inflammatory oxidised lipids. Ann Rheum Dis. 2011 Sep; 70(9):1619-24. PMID: 21670088; PMCID: PMC3147230.
    109. Haider L, Fischer MT, Frischer JM, Bauer J, Höftberger R, Botond G, Esterbauer H, Binder CJ, Witztum JL, Lassmann H. Oxidative damage in multiple sclerosis lesions. Brain. 2011 Jul; 134(Pt 7):1914-24. PMID: 21653539; PMCID: PMC3122372.
    110. von Vietinghoff S, Koltsova EK, Mestas J, Diehl CJ, Witztum JL, Ley K. Mycophenolate mofetil decreases atherosclerotic lesion size by depression of aortic T-lymphocyte and interleukin-17-mediated macrophage accumulation. J Am Coll Cardiol. 2011 May 24; 57(21):2194-204. PMID: 21596236; PMCID: PMC3378670.
    111. Merki E, Graham M, Taleb A, Leibundgut G, Yang X, Miller ER, Fu W, Mullick AE, Lee R, Willeit P, Crooke RM, Witztum JL, Tsimikas S. Antisense oligonucleotide lowers plasma levels of apolipoprotein (a) and lipoprotein (a) in transgenic mice. J Am Coll Cardiol. 2011 Apr 12; 57(15):1611-21. PMID: 21474042.
      View in: PubMed
    112. Diehl CJ, Barish GD, Downes M, Chou MY, Heinz S, Glass CK, Evans RM, Witztum JL. Research resource: Comparative nuclear receptor atlas: basal and activated peritoneal B-1 and B-2 cells. Mol Endocrinol. 2011 Mar; 25(3):529-45. PMID: 21273443; PMCID: PMC3045740.
    113. Miller YI, Choi SH, Wiesner P, Fang L, Harkewicz R, Hartvigsen K, Boullier A, Gonen A, Diehl CJ, Que X, Montano E, Shaw PX, Tsimikas S, Binder CJ, Witztum JL. Oxidation-specific epitopes are danger-associated molecular patterns recognized by pattern recognition receptors of innate immunity. Circ Res. 2011 Jan 21; 108(2):235-48. PMID: 21252151; PMCID: PMC3075542.
    114. Steinberg D, Witztum JL. Oxidized low-density lipoprotein and atherosclerosis. Arterioscler Thromb Vasc Biol. 2010 Dec; 30(12):2311-6. PMID: 21084697.
      View in: PubMed
    115. Bishop JR, Passos-Bueno MR, Fong L, Stanford KI, Gonzales JC, Yeh E, Young SG, Bensadoun A, Witztum JL, Esko JD, Moulton KS. Deletion of the basement membrane heparan sulfate proteoglycan type XVIII collagen causes hypertriglyceridemia in mice and humans. PLoS One. 2010 Nov 10; 5(11):e13919. PMID: 21085708; PMCID: PMC2978080.
    116. Seimon TA, Nadolski MJ, Liao X, Magallon J, Nguyen M, Feric NT, Koschinsky ML, Harkewicz R, Witztum JL, Tsimikas S, Golenbock D, Moore KJ, Tabas I. Atherogenic lipids and lipoproteins trigger CD36-TLR2-dependent apoptosis in macrophages undergoing endoplasmic reticulum stress. Cell Metab. 2010 Nov 03; 12(5):467-82. PMID: 21035758; PMCID: PMC2991104.
    117. Mendez-Fernandez YV, Stevenson BG, Diehl CJ, Braun NA, Wade NS, Covarrubias R, van Leuven S, Witztum JL, Major AS. The inhibitory Fc?RIIb modulates the inflammatory response and influences atherosclerosis in male apoE(-/-) mice. Atherosclerosis. 2011 Jan; 214(1):73-80. PMID: 21084088; PMCID: PMC3052995.
    118. Wool GD, Cabana VG, Lukens J, Shaw PX, Binder CJ, Witztum JL, Reardon CA, Getz GS. 4F Peptide reduces nascent atherosclerosis and induces natural antibody production in apolipoprotein E-null mice. FASEB J. 2011 Jan; 25(1):290-300. PMID: 20876212; PMCID: PMC3005429.
    119. Tsimikas S, Mallat Z, Talmud PJ, Kastelein JJ, Wareham NJ, Sandhu MS, Miller ER, Benessiano J, Tedgui A, Witztum JL, Khaw KT, Boekholdt SM. Oxidation-specific biomarkers, lipoprotein(a), and risk of fatal and nonfatal coronary events. J Am Coll Cardiol. 2010 Sep 14; 56(12):946-55. PMID: 20828647.
      View in: PubMed
    120. Faghihnia N, Tsimikas S, Miller ER, Witztum JL, Krauss RM. Changes in lipoprotein(a), oxidized phospholipids, and LDL subclasses with a low-fat high-carbohydrate diet. J Lipid Res. 2010 Nov; 51(11):3324-30. PMID: 20713651; PMCID: PMC2952573.
    121. Fang L, Harkewicz R, Hartvigsen K, Wiesner P, Choi SH, Almazan F, Pattison J, Deer E, Sayaphupha T, Dennis EA, Witztum JL, Tsimikas S, Miller YI. Oxidized cholesteryl esters and phospholipids in zebrafish larvae fed a high cholesterol diet: macrophage binding and activation. J Biol Chem. 2010 Oct 15; 285(42):32343-51. PMID: 20710028; PMCID: PMC2952235.
    122. Sun J, Hartvigsen K, Chou MY, Zhang Y, Sukhova GK, Zhang J, Lopez-Ilasaca M, Diehl CJ, Yakov N, Harats D, George J, Witztum JL, Libby P, Ploegh H, Shi GP. Deficiency of antigen-presenting cell invariant chain reduces atherosclerosis in mice. Circulation. 2010 Aug 24; 122(8):808-20. PMID: 20697023; PMCID: PMC2927799.
    123. Wiesner P, Choi SH, Almazan F, Benner C, Huang W, Diehl CJ, Gonen A, Butler S, Witztum JL, Glass CK, Miller YI. Low doses of lipopolysaccharide and minimally oxidized low-density lipoprotein cooperatively activate macrophages via nuclear factor kappa B and activator protein-1: possible mechanism for acceleration of atherosclerosis by subclinical endotoxemia. Circ Res. 2010 Jul 09; 107(1):56-65. PMID: 20489162; PMCID: PMC2904601.
    124. Yvan-Charvet L, Pagler TA, Seimon TA, Thorp E, Welch CL, Witztum JL, Tabas I, Tall AR. ABCA1 and ABCG1 protect against oxidative stress-induced macrophage apoptosis during efferocytosis. Circ Res. 2010 Jun 25; 106(12):1861-9. PMID: 20431058; PMCID: PMC2995809.
    125. Cardilo-Reis L, Witztum JL, Binder CJ. When monocytes come (too) close to our hearts. J Am Coll Cardiol. 2010 Apr 13; 55(15):1639-41. PMID: 20378084.
      View in: PubMed
    126. Shao B, Pennathur S, Pagani I, Oda MN, Witztum JL, Oram JF, Heinecke JW. Modifying apolipoprotein A-I by malondialdehyde, but not by an array of other reactive carbonyls, blocks cholesterol efflux by the ABCA1 pathway. J Biol Chem. 2010 Jun 11; 285(24):18473-84. PMID: 20378541; PMCID: PMC2881773.
    127. Kelly JA, Griffin ME, Fava RA, Wood SG, Bessette KA, Miller ER, Huber SA, Binder CJ, Witztum JL, Morganelli PM. Inhibition of arterial lesion progression in CD16-deficient mice: evidence for altered immunity and the role of IL-10. Cardiovasc Res. 2010 Jan 01; 85(1):224-31. PMID: 19720605; PMCID: PMC2791057.
    128. Pham T, Gregg CJ, Karp F, Chow R, Padler-Karavani V, Cao H, Chen X, Witztum JL, Varki NM, Varki A. Evidence for a novel human-specific xeno-auto-antibody response against vascular endothelium. Blood. 2009 Dec 10; 114(25):5225-35. PMID: 19828701; PMCID: PMC2792214.
    129. Durand CA, Hartvigsen K, Fogelstrand L, Kim S, Iritani S, Vanhaesebroeck B, Witztum JL, Puri KD, Gold MR. Phosphoinositide 3-kinase p110 delta regulates natural antibody production, marginal zone and B-1 B cell function, and autoantibody responses. J Immunol. 2009 Nov 01; 183(9):5673-84. PMID: 19843950.
      View in: PubMed
    130. Arai K, Luke MM, Koschinsky ML, Miller ER, Pullinger CR, Witztum JL, Kane JP, Tsimikas S. The I4399M variant of apolipoprotein(a) is associated with increased oxidized phospholipids on apolipoprotein B-100 particles. Atherosclerosis. 2010 Apr; 209(2):498-503. PMID: 19880117.
      View in: PubMed
    131. Stanford KI, Bishop JR, Foley EM, Gonzales JC, Niesman IR, Witztum JL, Esko JD. Syndecan-1 is the primary heparan sulfate proteoglycan mediating hepatic clearance of triglyceride-rich lipoproteins in mice. J Clin Invest. 2009 Nov; 119(11):3236-45. PMID: 19805913.
      View in: PubMed
    132. Crowe CR, Chen K, Pociask DA, Alcorn JF, Krivich C, Enelow RI, Ross TM, Witztum JL, Kolls JK. Critical role of IL-17RA in immunopathology of influenza infection. J Immunol. 2009 Oct 15; 183(8):5301-10. PMID: 19783685; PMCID: PMC3638739.
    133. Fraley AE, Schwartz GG, Olsson AG, Kinlay S, Szarek M, Rifai N, Libby P, Ganz P, Witztum JL, Tsimikas S. Relationship of oxidized phospholipids and biomarkers of oxidized low-density lipoprotein with cardiovascular risk factors, inflammatory biomarkers, and effect of statin therapy in patients with acute coronary syndromes: Results from the MIRACL (Myocardial Ischemia Reduction With Aggressive Cholesterol Lowering) trial. J Am Coll Cardiol. 2009 Jun 09; 53(23):2186-96. PMID: 19497447.
      View in: PubMed
    134. Steinberg D, Witztum JL. Inhibition of PCSK9: a powerful weapon for achieving ideal LDL cholesterol levels. Proc Natl Acad Sci U S A. 2009 Jun 16; 106(24):9546-7. PMID: 19506257; PMCID: PMC2701045.
    135. Choi SH, Harkewicz R, Lee JH, Boullier A, Almazan F, Li AC, Witztum JL, Bae YS, Miller YI. Lipoprotein accumulation in macrophages via toll-like receptor-4-dependent fluid phase uptake. Circ Res. 2009 Jun 19; 104(12):1355-63. PMID: 19461045; PMCID: PMC2741301.
    136. Gautier EL, Huby T, Saint-Charles F, Ouzilleau B, Pirault J, Deswaerte V, Ginhoux F, Miller ER, Witztum JL, Chapman MJ, Lesnik P. Conventional dendritic cells at the crossroads between immunity and cholesterol homeostasis in atherosclerosis. Circulation. 2009 May 05; 119(17):2367-75. PMID: 19380622.
      View in: PubMed
    137. Chou MY, Fogelstrand L, Hartvigsen K, Hansen LF, Woelkers D, Shaw PX, Choi J, Perkmann T, Bäckhed F, Miller YI, Hörkkö S, Corr M, Witztum JL, Binder CJ. Oxidation-specific epitopes are dominant targets of innate natural antibodies in mice and humans. J Clin Invest. 2009 May; 119(5):1335-49. PMID: 19363291; PMCID: PMC2673862.
    138. Dennis EA, Witztum JL. Fifty years of research on lipids. J Lipid Res. 2009 Apr; 50 Suppl:S1. PMID: 19346336; PMCID: PMC2674715.
    139. Tsimikas S, Clopton P, Brilakis ES, Marcovina SM, Khera A, Miller ER, de Lemos JA, Witztum JL. Relationship of oxidized phospholipids on apolipoprotein B-100 particles to race/ethnicity, apolipoprotein(a) isoform size, and cardiovascular risk factors: results from the Dallas Heart Study. Circulation. 2009 Apr 07; 119(13):1711-9. PMID: 19307470; PMCID: PMC2782388.
    140. Gautier EL, Huby T, Witztum JL, Ouzilleau B, Miller ER, Saint-Charles F, Aucouturier P, Chapman MJ, Lesnik P. Macrophage apoptosis exerts divergent effects on atherogenesis as a function of lesion stage. Circulation. 2009 Apr 07; 119(13):1795-804. PMID: 19307478.
      View in: PubMed
    141. Stoletov K, Fang L, Choi SH, Hartvigsen K, Hansen LF, Hall C, Pattison J, Juliano J, Miller ER, Almazan F, Crosier P, Witztum JL, Klemke RL, Miller YI. Vascular lipid accumulation, lipoprotein oxidation, and macrophage lipid uptake in hypercholesterolemic zebrafish. Circ Res. 2009 Apr 24; 104(8):952-60. PMID: 19265037; PMCID: PMC2834250.
    142. Hartvigsen K, Chou MY, Hansen LF, Shaw PX, Tsimikas S, Binder CJ, Witztum JL. The role of innate immunity in atherogenesis. J Lipid Res. 2009 Apr; 50 Suppl:S388-93. PMID: 19106070; PMCID: PMC2674727.
    143. Bae YS, Lee JH, Choi SH, Kim S, Almazan F, Witztum JL, Miller YI. Macrophages generate reactive oxygen species in response to minimally oxidized low-density lipoprotein: toll-like receptor 4- and spleen tyrosine kinase-dependent activation of NADPH oxidase 2. Circ Res. 2009 Jan 30; 104(2):210-8, 21p following 218. PMID: 19096031; PMCID: PMC2720065.
    144. Tsimikas S, Willeit J, Knoflach M, Mayr M, Egger G, Notdurfter M, Witztum JL, Wiedermann CJ, Xu Q, Kiechl S. Lipoprotein-associated phospholipase A2 activity, ferritin levels, metabolic syndrome, and 10-year cardiovascular and non-cardiovascular mortality: results from the Bruneck study. Eur Heart J. 2009 Jan; 30(1):107-15. PMID: 19019993.
      View in: PubMed
    145. Attie AD, Witztum JL, Edwards PA, Lusis JA. In memoriam: Roger A. Davis (1945-2008). J Lipid Res. 2008 Nov; 49(11):2279-80. PMID: 19123270.
      View in: PubMed
    146. Steinberg D, Glass CK, Witztum JL. Evidence mandating earlier and more aggressive treatment of hypercholesterolemia. Circulation. 2008 Aug 05; 118(6):672-7. PMID: 18678783.
      View in: PubMed
    147. Cruz D, Watson AD, Miller CS, Montoya D, Ochoa MT, Sieling PA, Gutierrez MA, Navab M, Reddy ST, Witztum JL, Fogelman AM, Rea TH, Eisenberg D, Berliner J, Modlin RL. Host-derived oxidized phospholipids and HDL regulate innate immunity in human leprosy. J Clin Invest. 2008 Aug; 118(8):2917-28. PMID: 18636118; PMCID: PMC2467381.
    148. Tsimikas S, Witztum JL. The role of oxidized phospholipids in mediating lipoprotein(a) atherogenicity. Curr Opin Lipidol. 2008 Aug; 19(4):369-77. PMID: 18607184.
      View in: PubMed
    149. Merki E, Graham MJ, Mullick AE, Miller ER, Crooke RM, Pitas RE, Witztum JL, Tsimikas S. Antisense oligonucleotide directed to human apolipoprotein B-100 reduces lipoprotein(a) levels and oxidized phospholipids on human apolipoprotein B-100 particles in lipoprotein(a) transgenic mice. Circulation. 2008 Aug 12; 118(7):743-53. PMID: 18663084.
      View in: PubMed
    150. Bergmark C, Dewan A, Orsoni A, Merki E, Miller ER, Shin MJ, Binder CJ, Hörkkö S, Krauss RM, Chapman MJ, Witztum JL, Tsimikas S. A novel function of lipoprotein [a] as a preferential carrier of oxidized phospholipids in human plasma. J Lipid Res. 2008 Oct; 49(10):2230-9. PMID: 18594118.
      View in: PubMed
    151. Choi SH, Chae A, Miller E, Messig M, Ntanios F, DeMaria AN, Nissen SE, Witztum JL, Tsimikas S. Relationship between biomarkers of oxidized low-density lipoprotein, statin therapy, quantitative coronary angiography, and atheroma: volume observations from the REVERSAL (Reversal of Atherosclerosis with Aggressive Lipid Lowering) study. J Am Coll Cardiol. 2008 Jul 01; 52(1):24-32. PMID: 18582631.
      View in: PubMed
    152. Briley-Saebo KC, Shaw PX, Mulder WJ, Choi SH, Vucic E, Aguinaldo JG, Witztum JL, Fuster V, Tsimikas S, Fayad ZA. Targeted molecular probes for imaging atherosclerotic lesions with magnetic resonance using antibodies that recognize oxidation-specific epitopes. Circulation. 2008 Jun 24; 117(25):3206-15. PMID: 18541740; PMCID: PMC4492476.
    153. Ky B, Burke A, Tsimikas S, Wolfe ML, Tadesse MG, Szapary PO, Witztum JL, FitzGerald GA, Rader DJ. The influence of pravastatin and atorvastatin on markers of oxidative stress in hypercholesterolemic humans. J Am Coll Cardiol. 2008 Apr 29; 51(17):1653-62. PMID: 18436117.
      View in: PubMed
    154. Brunzell JD, Davidson M, Furberg CD, Goldberg RB, Howard BV, Stein JH, Witztum JL. Lipoprotein management in patients with cardiometabolic risk: consensus conference report from the American Diabetes Association and the American College of Cardiology Foundation. J Am Coll Cardiol. 2008 Apr 15; 51(15):1512-24. PMID: 18402913.
      View in: PubMed
    155. Brunzell JD, Davidson M, Furberg CD, Goldberg RB, Howard BV, Stein JH, Witztum JL. Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology Foundation. Diabetes Care. 2008 Apr; 31(4):811-22. PMID: 18375431.
      View in: PubMed
    156. Binder CJ, Chou MY, Fogelstrand L, Hartvigsen K, Shaw PX, Boullier A, Witztum JL. Natural antibodies in murine atherosclerosis. Curr Drug Targets. 2008 Mar; 9(3):190-5. PMID: 18336236.
      View in: PubMed
    157. Harkewicz R, Hartvigsen K, Almazan F, Dennis EA, Witztum JL, Miller YI. Cholesteryl ester hydroperoxides are biologically active components of minimally oxidized low density lipoprotein. J Biol Chem. 2008 Apr 18; 283(16):10241-51. PMID: 18263582; PMCID: PMC2447632.
    158. Binder CJ, Hartvigsen K, Witztum JL. Promise of immune modulation to inhibit atherogenesis. J Am Coll Cardiol. 2007 Aug 07; 50(6):547-50. PMID: 17678739.
      View in: PubMed
    159. Kiechl S, Willeit J, Mayr M, Viehweider B, Oberhollenzer M, Kronenberg F, Wiedermann CJ, Oberthaler S, Xu Q, Witztum JL, Tsimikas S. Oxidized phospholipids, lipoprotein(a), lipoprotein-associated phospholipase A2 activity, and 10-year cardiovascular outcomes: prospective results from the Bruneck study. Arterioscler Thromb Vasc Biol. 2007 Aug; 27(8):1788-95. PMID: 17541022.
      View in: PubMed
    160. Bro S, Binder CJ, Witztum JL, Olgaard K, Nielsen LB. Inhibition of the renin-angiotensin system abolishes the proatherogenic effect of uremia in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol. 2007 May; 27(5):1080-6. PMID: 17347482.
      View in: PubMed
    161. Wessel J, Moratorio G, Rao F, Mahata M, Zhang L, Greene W, Rana BK, Kennedy BP, Khandrika S, Huang P, Lillie EO, Shih PA, Smith DW, Wen G, Hamilton BA, Ziegler MG, Witztum JL, Schork NJ, Schmid-Schönbein GW, O'Connor DT. C-reactive protein, an 'intermediate phenotype' for inflammation: human twin studies reveal heritability, association with blood pressure and the metabolic syndrome, and the influence of common polymorphism at catecholaminergic/beta-adrenergic pathway loci. J Hypertens. 2007 Feb; 25(2):329-43. PMID: 17211240.
      View in: PubMed
    162. Feng X, Li H, Rumbin AA, Wang X, La Cava A, Brechtelsbauer K, Castellani LW, Witztum JL, Lusis AJ, Tsao BP. ApoE-/-Fas-/- C57BL/6 mice: a novel murine model simultaneously exhibits lupus nephritis, atherosclerosis, and osteopenia. J Lipid Res. 2007 Apr; 48(4):794-805. PMID: 17259598.
      View in: PubMed
    163. Hartvigsen K, Binder CJ, Hansen LF, Rafia A, Juliano J, Hörkkö S, Steinberg D, Palinski W, Witztum JL, Li AC. A diet-induced hypercholesterolemic murine model to study atherogenesis without obesity and metabolic syndrome. Arterioscler Thromb Vasc Biol. 2007 Apr; 27(4):878-85. PMID: 17255537.
      View in: PubMed
    164. MacArthur JM, Bishop JR, Stanford KI, Wang L, Bensadoun A, Witztum JL, Esko JD. Liver heparan sulfate proteoglycans mediate clearance of triglyceride-rich lipoproteins independently of LDL receptor family members. J Clin Invest. 2007 Jan; 117(1):153-64. PMID: 17200715; PMCID: PMC1716206.
    165. Tsimikas S, Brilakis ES, Lennon RJ, Miller ER, Witztum JL, McConnell JP, Kornman KS, Berger PB. Relationship of IgG and IgM autoantibodies to oxidized low density lipoprotein with coronary artery disease and cardiovascular events. J Lipid Res. 2007 Feb; 48(2):425-33. PMID: 17093289.
      View in: PubMed
    166. Tsimikas S, Aikawa M, Miller FJ, Miller ER, Torzewski M, Lentz SR, Bergmark C, Heistad DD, Libby P, Witztum JL. Increased plasma oxidized phospholipid:apolipoprotein B-100 ratio with concomitant depletion of oxidized phospholipids from atherosclerotic lesions after dietary lipid-lowering: a potential biomarker of early atherosclerosis regression. Arterioscler Thromb Vasc Biol. 2007 Jan; 27(1):175-81. PMID: 17082490.
      View in: PubMed
    167. Gotsman I, Grabie N, Gupta R, Dacosta R, MacConmara M, Lederer J, Sukhova G, Witztum JL, Sharpe AH, Lichtman AH. Impaired regulatory T-cell response and enhanced atherosclerosis in the absence of inducible costimulatory molecule. Circulation. 2006 Nov 07; 114(19):2047-55. PMID: 17060381.
      View in: PubMed
    168. Tuominen A, Miller YI, Hansen LF, Kesäniemi YA, Witztum JL, Hörkkö S. A natural antibody to oxidized cardiolipin binds to oxidized low-density lipoprotein, apoptotic cells, and atherosclerotic lesions. Arterioscler Thromb Vasc Biol. 2006 Sep; 26(9):2096-102. PMID: 16794225.
      View in: PubMed
    169. Zipes DP, Zvaifler NJ, Glassock RJ, Gilman S, Muñoz A, Gogolak V, Gordis L, Dedon PC, Guengerich FP, Wasserman SI, Witztum JL, Wogan GN. Rosuvastatin: an independent analysis of risks and benefits. MedGenMed. 2006 Jun 14; 8(2):73. PMID: 16926812; PMCID: PMC1785157.
    170. Mayr M, Kiechl S, Tsimikas S, Miller E, Sheldon J, Willeit J, Witztum JL, Xu Q. Oxidized low-density lipoprotein autoantibodies, chronic infections, and carotid atherosclerosis in a population-based study. J Am Coll Cardiol. 2006 Jun 20; 47(12):2436-43. PMID: 16781371.
      View in: PubMed
    171. Tsimikas S, Kiechl S, Willeit J, Mayr M, Miller ER, Kronenberg F, Xu Q, Bergmark C, Weger S, Oberhollenzer F, Witztum JL. Oxidized phospholipids predict the presence and progression of carotid and femoral atherosclerosis and symptomatic cardiovascular disease: five-year prospective results from the Bruneck study. J Am Coll Cardiol. 2006 Jun 06; 47(11):2219-28. PMID: 16750687.
      View in: PubMed
    172. Rodenburg J, Vissers MN, Wiegman A, Miller ER, Ridker PM, Witztum JL, Kastelein JJ, Tsimikas S. Oxidized low-density lipoprotein in children with familial hypercholesterolemia and unaffected siblings: effect of pravastatin. J Am Coll Cardiol. 2006 May 02; 47(9):1803-10. PMID: 16682304.
      View in: PubMed
    173. Boullier A, Li Y, Quehenberger O, Palinski W, Tabas I, Witztum JL, Miller YI. Minimally oxidized LDL offsets the apoptotic effects of extensively oxidized LDL and free cholesterol in macrophages. Arterioscler Thromb Vasc Biol. 2006 May; 26(5):1169-76. PMID: 16484596.
      View in: PubMed
    174. Wilson PW, Ben-Yehuda O, McNamara J, Massaro J, Witztum J, Reaven PD. Autoantibodies to oxidized LDL and cardiovascular risk: the Framingham Offspring Study. Atherosclerosis. 2006 Dec; 189(2):364-8. PMID: 16476434.
      View in: PubMed
    175. Segev A, Strauss BH, Witztum JL, Lau HK, Tsimikas S. Relationship of a comprehensive panel of plasma oxidized low-density lipoprotein markers to angiographic restenosis in patients undergoing percutaneous coronary intervention for stable angina. Am Heart J. 2005 Nov; 150(5):1007-14. PMID: 16290986.
      View in: PubMed
    176. Witztum JL. You are right too! J Clin Invest. 2005 Aug; 115(8):2072-5. PMID: 16075051; PMCID: PMC1180570.
    177. Tsimikas S, Brilakis ES, Miller ER, McConnell JP, Lennon RJ, Kornman KS, Witztum JL, Berger PB. Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease. N Engl J Med. 2005 Jul 07; 353(1):46-57. PMID: 16000355.
      View in: PubMed
    178. Arakawa H, Qian JY, Baatar D, Karasawa K, Asada Y, Sasaguri Y, Miller ER, Witztum JL, Ueno H. Local expression of platelet-activating factor-acetylhydrolase reduces accumulation of oxidized lipoproteins and inhibits inflammation, shear stress-induced thrombosis, and neointima formation in balloon-injured carotid arteries in nonhyperlipidemic rabbits. Circulation. 2005 Jun 21; 111(24):3302-9. PMID: 15956136.
      View in: PubMed
    179. Binder CJ, Shaw PX, Chang MK, Boullier A, Hartvigsen K, Hörkkö S, Miller YI, Woelkers DA, Corr M, Witztum JL. The role of natural antibodies in atherogenesis. J Lipid Res. 2005 Jul; 46(7):1353-63. PMID: 15897601.
      View in: PubMed
    180. Miller YI, Viriyakosol S, Worrall DS, Boullier A, Butler S, Witztum JL. Toll-like receptor 4-dependent and -independent cytokine secretion induced by minimally oxidized low-density lipoprotein in macrophages. Arterioscler Thromb Vasc Biol. 2005 Jun; 25(6):1213-9. PMID: 15718493.
      View in: PubMed
    181. Fahy E, Subramaniam S, Brown HA, Glass CK, Merrill AH, Murphy RC, Raetz CR, Russell DW, Seyama Y, Shaw W, Shimizu T, Spener F, van Meer G, VanNieuwenhze MS, White SH, Witztum JL, Dennis EA. A comprehensive classification system for lipids. J Lipid Res. 2005 May; 46(5):839-61. PMID: 15722563.
      View in: PubMed
    182. Boullier A, Friedman P, Harkewicz R, Hartvigsen K, Green SR, Almazan F, Dennis EA, Steinberg D, Witztum JL, Quehenberger O. Phosphocholine as a pattern recognition ligand for CD36. J Lipid Res. 2005 May; 46(5):969-76. PMID: 15722561.
      View in: PubMed
    183. Buono C, Binder CJ, Stavrakis G, Witztum JL, Glimcher LH, Lichtman AH. T-bet deficiency reduces atherosclerosis and alters plaque antigen-specific immune responses. Proc Natl Acad Sci U S A. 2005 Feb 01; 102(5):1596-601. PMID: 15665085; PMCID: PMC547865.
    184. Schneider M, Witztum JL, Young SG, Ludwig EH, Miller ER, Tsimikas S, Curtiss LK, Marcovina SM, Taylor JM, Lawn RM, Innerarity TL, Pitas RE. High-level lipoprotein [a] expression in transgenic mice: evidence for oxidized phospholipids in lipoprotein [a] but not in low density lipoproteins. J Lipid Res. 2005 Apr; 46(4):769-78. PMID: 15654123.
      View in: PubMed
    185. Frostegård J, Svenungsson E, Wu R, Gunnarsson I, Lundberg IE, Klareskog L, Hörkkö S, Witztum JL. Lipid peroxidation is enhanced in patients with systemic lupus erythematosus and is associated with arterial and renal disease manifestations. Arthritis Rheum. 2005 Jan; 52(1):192-200. PMID: 15641060.
      View in: PubMed
    186. Chang MK, Binder CJ, Miller YI, Subbanagounder G, Silverman GJ, Berliner JA, Witztum JL. Apoptotic cells with oxidation-specific epitopes are immunogenic and proinflammatory. J Exp Med. 2004 Dec 06; 200(11):1359-70. PMID: 15583011; PMCID: PMC2211955.
    187. Li AC, Binder CJ, Gutierrez A, Brown KK, Plotkin CR, Pattison JW, Valledor AF, Davis RA, Willson TM, Witztum JL, Palinski W, Glass CK. Differential inhibition of macrophage foam-cell formation and atherosclerosis in mice by PPARalpha, beta/delta, and gamma. J Clin Invest. 2004 Dec; 114(11):1564-76. PMID: 15578089; PMCID: PMC529277.
    188. Torzewski M, Shaw PX, Han KR, Shortal B, Lackner KJ, Witztum JL, Palinski W, Tsimikas S. Reduced in vivo aortic uptake of radiolabeled oxidation-specific antibodies reflects changes in plaque composition consistent with plaque stabilization. Arterioscler Thromb Vasc Biol. 2004 Dec; 24(12):2307-12. PMID: 15528482.
      View in: PubMed
    189. Schneider M, Vergès B, Klein A, Miller ER, Deckert V, Desrumaux C, Masson D, Gambert P, Brun JM, Fruchart-Najib J, Blache D, Witztum JL, Lagrost L. Alterations in plasma vitamin E distribution in type 2 diabetic patients with elevated plasma phospholipid transfer protein activity. Diabetes. 2004 Oct; 53(10):2633-9. PMID: 15448094.
      View in: PubMed
    190. Huo Y, Zhao L, Hyman MC, Shashkin P, Harry BL, Burcin T, Forlow SB, Stark MA, Smith DF, Clarke S, Srinivasan S, Hedrick CC, Praticò D, Witztum JL, Nadler JL, Funk CD, Ley K. Critical role of macrophage 12/15-lipoxygenase for atherosclerosis in apolipoprotein E-deficient mice. Circulation. 2004 Oct 05; 110(14):2024-31. PMID: 15451785.
      View in: PubMed
    191. Tsimikas S, Witztum JL, Miller ER, Sasiela WJ, Szarek M, Olsson AG, Schwartz GG. High-dose atorvastatin reduces total plasma levels of oxidized phospholipids and immune complexes present on apolipoprotein B-100 in patients with acute coronary syndromes in the MIRACL trial. Circulation. 2004 Sep 14; 110(11):1406-12. PMID: 15353498.
      View in: PubMed
    192. Choudhury RP, Rong JX, Trogan E, Elmalem VI, Dansky HM, Breslow JL, Witztum JL, Fallon JT, Fisher EA. High-density lipoproteins retard the progression of atherosclerosis and favorably remodel lesions without suppressing indices of inflammation or oxidation. Arterioscler Thromb Vasc Biol. 2004 Oct; 24(10):1904-9. PMID: 15319266.
      View in: PubMed
    193. Kris-Etherton PM, Lichtenstein AH, Howard BV, Steinberg D, Witztum JL. Antioxidant vitamin supplements and cardiovascular disease. Circulation. 2004 Aug 03; 110(5):637-41. PMID: 15289389.
      View in: PubMed
    194. Binder CJ, Hartvigsen K, Chang MK, Miller M, Broide D, Palinski W, Curtiss LK, Corr M, Witztum JL. IL-5 links adaptive and natural immunity specific for epitopes of oxidized LDL and protects from atherosclerosis. J Clin Invest. 2004 Aug; 114(3):427-37. PMID: 15286809; PMCID: PMC484976.
    195. Soep JB, Mietus-Snyder M, Malloy MJ, Witztum JL, von Scheven E. Assessment of atherosclerotic risk factors and endothelial function in children and young adults with pediatric-onset systemic lupus erythematosus. Arthritis Rheum. 2004 Jun 15; 51(3):451-7. PMID: 15188333.
      View in: PubMed
    196. Tsimikas S, Lau HK, Han KR, Shortal B, Miller ER, Segev A, Curtiss LK, Witztum JL, Strauss BH. Percutaneous coronary intervention results in acute increases in oxidized phospholipids and lipoprotein(a): short-term and long-term immunologic responses to oxidized low-density lipoprotein. Circulation. 2004 Jun 29; 109(25):3164-70. PMID: 15184281.
      View in: PubMed
    197. Reardon CA, Miller ER, Blachowicz L, Lukens J, Binder CJ, Witztum JL, Getz GS. Autoantibodies to OxLDL fail to alter the clearance of injected OxLDL in apolipoprotein E-deficient mice. J Lipid Res. 2004 Jul; 45(7):1347-54. PMID: 15102879.
      View in: PubMed
    198. Kinlay S, Behrendt D, Fang JC, Delagrange D, Morrow J, Witztum JL, Rifai N, Selwyn AP, Creager MA, Ganz P. Long-term effect of combined vitamins E and C on coronary and peripheral endothelial function. J Am Coll Cardiol. 2004 Feb 18; 43(4):629-34. PMID: 14975474.
      View in: PubMed
    199. Rock CL, Flatt SW, Thomson CA, Stefanick ML, Newman VA, Jones L, Natarajan L, Pierce JP, Chang RJ, Witztum JL. Plasma triacylglycerol and HDL cholesterol concentrations confirm self-reported changes in carbohydrate and fat intakes in women in a diet intervention trial. J Nutr. 2004 Feb; 134(2):342-7. PMID: 14747670.
      View in: PubMed
    200. Silaste ML, Rantala M, Alfthan G, Aro A, Witztum JL, Kesäniemi YA, Hörkkö S. Changes in dietary fat intake alter plasma levels of oxidized low-density lipoprotein and lipoprotein(a). Arterioscler Thromb Vasc Biol. 2004 Mar; 24(3):498-503. PMID: 14739118.
      View in: PubMed
    201. Frostegård J, Wu R, Lemne C, Thulin T, Witztum JL, de Faire U. Circulating oxidized low-density lipoprotein is increased in hypertension. Clin Sci (Lond). 2003 Nov; 105(5):615-20. PMID: 12837127.
      View in: PubMed
    202. Edelstein C, Pfaffinger D, Hinman J, Miller E, Lipkind G, Tsimikas S, Bergmark C, Getz GS, Witztum JL, Scanu AM. Lysine-phosphatidylcholine adducts in kringle V impart unique immunological and potential pro-inflammatory properties to human apolipoprotein(a). J Biol Chem. 2003 Dec 26; 278(52):52841-7. PMID: 14557258.
      View in: PubMed
    203. Miller YI, Chang MK, Binder CJ, Shaw PX, Witztum JL. Oxidized low density lipoprotein and innate immune receptors. Curr Opin Lipidol. 2003 Oct; 14(5):437-45. PMID: 14501582.
      View in: PubMed
    204. Russell AP, Gastaldi G, Bobbioni-Harsch E, Arboit P, Gobelet C, Dériaz O, Golay A, Witztum JL, Giacobino JP. Lipid peroxidation in skeletal muscle of obese as compared to endurance-trained humans: a case of good vs. bad lipids? FEBS Lett. 2003 Sep 11; 551(1-3):104-6. PMID: 12965212.
      View in: PubMed
    205. Engler MM, Engler MB, Malloy MJ, Chiu EY, Schloetter MC, Paul SM, Stuehlinger M, Lin KY, Cooke JP, Morrow JD, Ridker PM, Rifai N, Miller E, Witztum JL, Mietus-Snyder M. Antioxidant vitamins C and E improve endothelial function in children with hyperlipidemia: Endothelial Assessment of Risk from Lipids in Youth (EARLY) Trial. Circulation. 2003 Sep 02; 108(9):1059-63. PMID: 12912807.
      View in: PubMed
    206. Miller YI, Worrall DS, Funk CD, Feramisco JR, Witztum JL. Actin polymerization in macrophages in response to oxidized LDL and apoptotic cells: role of 12/15-lipoxygenase and phosphoinositide 3-kinase. Mol Biol Cell. 2003 Oct; 14(10):4196-206. PMID: 14517329; PMCID: PMC207011.
    207. Shaw PX, Goodyear CS, Chang MK, Witztum JL, Silverman GJ. The autoreactivity of anti-phosphorylcholine antibodies for atherosclerosis-associated neo-antigens and apoptotic cells. J Immunol. 2003 Jun 15; 170(12):6151-7. PMID: 12794145.
      View in: PubMed
    208. Binder CJ, Hörkkö S, Dewan A, Chang MK, Kieu EP, Goodyear CS, Shaw PX, Palinski W, Witztum JL, Silverman GJ. Pneumococcal vaccination decreases atherosclerotic lesion formation: molecular mimicry between Streptococcus pneumoniae and oxidized LDL. Nat Med. 2003 Jun; 9(6):736-43. PMID: 12740573.
      View in: PubMed
    209. Sukhova GK, Zhang Y, Pan JH, Wada Y, Yamamoto T, Naito M, Kodama T, Tsimikas S, Witztum JL, Lu ML, Sakara Y, Chin MT, Libby P, Shi GP. Deficiency of cathepsin S reduces atherosclerosis in LDL receptor-deficient mice. J Clin Invest. 2003 Mar; 111(6):897-906. PMID: 12639996; PMCID: PMC153760.
    210. Tsimikas S, Bergmark C, Beyer RW, Patel R, Pattison J, Miller E, Juliano J, Witztum JL. Temporal increases in plasma markers of oxidized low-density lipoprotein strongly reflect the presence of acute coronary syndromes. J Am Coll Cardiol. 2003 Feb 05; 41(3):360-70. PMID: 12575961.
      View in: PubMed
    211. Tsimikas S, Witztum JL. Shifting the diagnosis and treatment of atherosclerosis to children and young adults: a new paradigm for the 21st century. J Am Coll Cardiol. 2002 Dec 18; 40(12):2122-4. PMID: 12505223.
      View in: PubMed
    212. Fang JC, Kinlay S, Behrendt D, Hikita H, Witztum JL, Selwyn AP, Ganz P. Circulating autoantibodies to oxidized LDL correlate with impaired coronary endothelial function after cardiac transplantation. Arterioscler Thromb Vasc Biol. 2002 Dec 01; 22(12):2044-8. PMID: 12482832.
      View in: PubMed
    213. Miller YI, Viriyakosol S, Binder CJ, Feramisco JR, Kirkland TN, Witztum JL. Minimally modified LDL binds to CD14, induces macrophage spreading via TLR4/MD-2, and inhibits phagocytosis of apoptotic cells. J Biol Chem. 2003 Jan 17; 278(3):1561-8. PMID: 12424240.
      View in: PubMed
    214. Binder CJ, Chang MK, Shaw PX, Miller YI, Hartvigsen K, Dewan A, Witztum JL. Innate and acquired immunity in atherogenesis. Nat Med. 2002 Nov; 8(11):1218-26. PMID: 12411948.
      View in: PubMed
    215. Chang MK, Binder CJ, Torzewski M, Witztum JL. C-reactive protein binds to both oxidized LDL and apoptotic cells through recognition of a common ligand: Phosphorylcholine of oxidized phospholipids. Proc Natl Acad Sci U S A. 2002 Oct 01; 99(20):13043-8. PMID: 12244213; PMCID: PMC130583.
    216. Aikawa M, Sugiyama S, Hill CC, Voglic SJ, Rabkin E, Fukumoto Y, Schoen FJ, Witztum JL, Libby P. Lipid lowering reduces oxidative stress and endothelial cell activation in rabbit atheroma. Circulation. 2002 Sep 10; 106(11):1390-6. PMID: 12221058.
      View in: PubMed
    217. Bannykh SI, Witztum JL, Bergmark C. Mechanical aortic injury in apoE-deficient mice as a model for development of atherosclerosis: demonstration of leukocyte rolling early after injury. Ultrastruct Pathol. 2002 Jul-Aug; 26(4):251-60. PMID: 12227951.
      View in: PubMed
    218. Buono C, Come CE, Witztum JL, Maguire GF, Connelly PW, Carroll M, Lichtman AH. Influence of C3 deficiency on atherosclerosis. Circulation. 2002 Jun 25; 105(25):3025-31. PMID: 12081998.
      View in: PubMed
    219. Jiang XC, Tall AR, Qin S, Lin M, Schneider M, Lalanne F, Deckert V, Desrumaux C, Athias A, Witztum JL, Lagrost L. Phospholipid transfer protein deficiency protects circulating lipoproteins from oxidation due to the enhanced accumulation of vitamin E. J Biol Chem. 2002 Aug 30; 277(35):31850-6. PMID: 12105225.
      View in: PubMed
    220. Steinberg D, Witztum JL. Is the oxidative modification hypothesis relevant to human atherosclerosis? Do the antioxidant trials conducted to date refute the hypothesis? Circulation. 2002 Apr 30; 105(17):2107-11. PMID: 11980692.
      View in: PubMed
    221. Witztum JL. Splenic immunity and atherosclerosis: a glimpse into a novel paradigm? J Clin Invest. 2002 Mar; 109(6):721-4. PMID: 11901180; PMCID: PMC150921.
    222. Huber J, Vales A, Mitulovic G, Blumer M, Schmid R, Witztum JL, Binder BR, Leitinger N. Oxidized membrane vesicles and blebs from apoptotic cells contain biologically active oxidized phospholipids that induce monocyte-endothelial interactions. Arterioscler Thromb Vasc Biol. 2002 Jan; 22(1):101-7. PMID: 11788468.
      View in: PubMed
    223. Subbanagounder G, Wong JW, Lee H, Faull KF, Miller E, Witztum JL, Berliner JA. Epoxyisoprostane and epoxycyclopentenone phospholipids regulate monocyte chemotactic protein-1 and interleukin-8 synthesis. Formation of these oxidized phospholipids in response to interleukin-1beta. J Biol Chem. 2002 Mar 01; 277(9):7271-81. PMID: 11751881.
      View in: PubMed
    224. Friedman P, Horkko S, Steinberg D, Witztum JL, Dennis EA. Correlation of antiphospholipid antibody recognition with the structure of synthetic oxidized phospholipids. Importance of Schiff base formation and aldol condensation. J Biol Chem. 2002 Mar 01; 277(9):7010-20. PMID: 11744722.
      View in: PubMed
    225. Witztum JL, Steinberg D. The oxidative modification hypothesis of atherosclerosis: does it hold for humans? Trends Cardiovasc Med. 2001 Apr-May; 11(3-4):93-102. PMID: 11686009.
      View in: PubMed
    Joseph's Networks
    Concepts
    Derived automatically from this person's publications.
    _
    Co-Authors
    People in Profiles who have published with this person.
    _
    Related Authors
    People who share related concepts with this person.
    _